# Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

> **NCT03080077** · PHASE3 · UNKNOWN · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 8 (actual)

## Conditions studied

- Keratoconus
- Ectasia

## Interventions

- **DRUG:** Ricrolin+
- **DRUG:** Epi-Off

## Key facts

- **NCT ID:** NCT03080077
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080077, "Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03080077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*